C 013: PROMISES & CHALLENGES OF MICRORNAS IN MULTIPLE MYELOMA THERAPY

Excerpt:


J Pharm Pharmacogn Res 2(Suppl. 1): S30, 2014 Special supplement with the abstract book of LATINFARMA 2013 Conference C 013: PROMISES & CHALLENGES OF MICRORNAS IN MULTIPLE MYELOMA THERAPY Palagani A1, Stefan Naulaerts2, Ken Op de Beeck3, Vandesompele J4, Mestdagh F4, Guy Van Camp3, Kris Laukens2,Vanden Berghe W.1 1Laboratory of Protein Chemistry, Proteomics and Epigenetic … Continue reading C 013: PROMISES & CHALLENGES OF MICRORNAS IN MULTIPLE MYELOMA THERAPY

J Pharm Pharmacogn Res 2(Suppl. 1): S30, 2014

Special supplement with the abstract book of LATINFARMA 2013

Conference

C 013: PROMISES & CHALLENGES OF MICRORNAS IN MULTIPLE MYELOMA THERAPY

Palagani A1, Stefan Naulaerts2, Ken Op de Beeck3, Vandesompele J4, Mestdagh F4, Guy Van Camp3, Kris Laukens2,Vanden Berghe W.1

1Laboratory of Protein Chemistry, Proteomics and Epigenetic Signalling,2Department of Mathematics and Computer Science,3Center of Medical Genetics, Department of Biomedical Sciences, University of Antwerp, Belgium.
4Center for Medical Genetics, Ghent University, Belgium.
Abstract

Multiple myeloma (MM) is an incurable plasma cell malignancy and is the second most common hematological cancer. It is characterized by complex, recurrent genetic and epigenetic abnormalities. Perturbed transcription of various noncoding miRNAs has been demonstrated in MM and their functional roles in MM pathogenesis and therapy response just starts to be unraveled. miRNAs are about 20 nucleotide, single strand, non-coding RNAs that may act as tumor suppressors or oncogenes and regulate gene expression by mRNA degradation or translational repression of hundreds of genes, often in a tissue-specific manner. As such, miRNA dysregulation can have profound cellular consequences. Whereas the loss of tumour-suppressive miRNAs enhances the expression of target oncogenes, increased expression of oncogenic miRNAs (known as oncomirs) can repress target tumour suppressor genes. This creates complex networks regulating a large variety of cellular processes, including differentiation, development, apoptosis and cell cycle progression. Understanding the molecular biology of myeloma also requires linking the miRNome to genomic, transcriptomic, epigenomic and proteomic features of malignant plasma cells. Integrative analysis based on computational target prediction, quantitative proteomics and miRNA/mRNA profiling revealed various functional miRNA-target regulatory networks supported by expression data. We will discuss convergence of microRNA regulation and nuclear factor-κB (NF-κB) and glucocorticoid pathways in MM therapy response. As such, interfering with microRNAs in myeloma regulatory networks holds promise to overcome drug resistance, which may improve clinical outcome.

Phyllanthus emblica flavonoid glycosides against xanthine oxidase
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1067-1078, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.1959_12.6.1067 Original Article Antioxidant potential and xanthine oxidase inhibition of flavonol glycosides from Phyllanthus emblica L. leaves [Potencial antioxidante e inhibición de la xantina oxidasa de los glucósidos de flavonol de las hojas de Phyllanthus emblica L.] Husnunnisa1, Rika Hartati1, Rachmat Mauludin2, … Continue reading Phyllanthus emblica flavonoid glycosides against xanthine oxidase
Spray-drying Perilla frutescens extract optimization
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1056-1066, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.2009_12.6.1056 Original Article Optimization of spray-drying conditions and quality assessment of dry extract from Perilla frutescens (L.) Britton leaves [Optimización de las condiciones de secado por atomización y evaluación de la calidad del extracto seco de hojas de Perilla frutescens (L.) Britton] … Continue reading Spray-drying Perilla frutescens extract optimization
Honey clinical applications in complementary medicine
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1040-1055, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.1870_12.6.1040 Review Honey clinical applications in complementary medicine: A critical review [Aplicaciones clínicas de la miel en la medicina complementaria: Una revisión crítica] Thai Hau Koo1, Andee Dzulkarnaen Zakaria2*, Mohd Zulkifli Mustafa3 1Department of Internal Medicine, School of Medical Sciences, Universiti Sains … Continue reading Honey clinical applications in complementary medicine

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio